MX2023007032A - Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas. - Google Patents

Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas.

Info

Publication number
MX2023007032A
MX2023007032A MX2023007032A MX2023007032A MX2023007032A MX 2023007032 A MX2023007032 A MX 2023007032A MX 2023007032 A MX2023007032 A MX 2023007032A MX 2023007032 A MX2023007032 A MX 2023007032A MX 2023007032 A MX2023007032 A MX 2023007032A
Authority
MX
Mexico
Prior art keywords
bifunctional molecules
protein degradation
targeted protein
novel bifunctional
targeted
Prior art date
Application number
MX2023007032A
Other languages
English (en)
Inventor
Michael Mathieson
Andrea Testa
Callum Macgregor
David Mcgarry
Gregor Meier
Ian Churcher
Original Assignee
Amphista Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2020186.9A external-priority patent/GB202020186D0/en
Priority claimed from GBGB2102494.8A external-priority patent/GB202102494D0/en
Application filed by Amphista Therapeutics Ltd filed Critical Amphista Therapeutics Ltd
Publication of MX2023007032A publication Critical patent/MX2023007032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a una nueva clase de moléculas bifuncionales que son útiles en una degradación dirigida o selectiva de una proteína.
MX2023007032A 2020-12-18 2021-12-16 Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas. MX2023007032A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2020186.9A GB202020186D0 (en) 2020-12-18 2020-12-18 Novel bifunctional molecules for targeted protein degradation
GBGB2102494.8A GB202102494D0 (en) 2021-02-22 2021-02-22 Novel bifunctional molecules for targeted protein degredation
PCT/GB2021/053332 WO2022129925A1 (en) 2020-12-18 2021-12-16 Novel bifunctional molecules for targeted protein degradation

Publications (1)

Publication Number Publication Date
MX2023007032A true MX2023007032A (es) 2023-07-18

Family

ID=79164461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007032A MX2023007032A (es) 2020-12-18 2021-12-16 Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas.

Country Status (12)

Country Link
US (1) US20240115711A1 (es)
EP (1) EP4263511A1 (es)
JP (1) JP2024505328A (es)
KR (1) KR20230137889A (es)
AU (1) AU2021400059A1 (es)
CA (1) CA3201962A1 (es)
CL (1) CL2023001735A1 (es)
CO (1) CO2023007768A2 (es)
IL (1) IL303717A (es)
MX (1) MX2023007032A (es)
PE (1) PE20240545A1 (es)
WO (1) WO2022129925A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023242597A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
WO2023242598A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
WO2024057021A1 (en) 2022-09-13 2024-03-21 Amphista Therapeutics Limited Compounds for targeted protein degradation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126251T2 (de) * 1990-02-08 1997-09-25 Eisai Co Ltd Benzensulfonamidderivat
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
RU2376286C2 (ru) * 2004-03-11 2009-12-20 Актелион Фармасьютиклз Лтд Производные индол-1-илуксусной кислоты
RU59063U1 (ru) 2006-05-30 2006-12-10 Государственное образовательное учреждение высшего профессионального образования "Ульяновский государственный технический университет" Режущий инструмент с многослойным покрытием
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
AU2018369759B2 (en) 2017-11-15 2022-11-24 Array Biopharma Inc. KRas G12C inhibitors
CA3103205A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
JP2021527137A (ja) 2018-06-13 2021-10-11 アンフィスタ セラピューティクス リミテッド Ｒｐｎ１１を標的化するための二機能性分子

Also Published As

Publication number Publication date
CA3201962A1 (en) 2022-06-23
US20240115711A1 (en) 2024-04-11
EP4263511A1 (en) 2023-10-25
IL303717A (en) 2023-08-01
CL2023001735A1 (es) 2024-02-16
AU2021400059A1 (en) 2023-07-06
PE20240545A1 (es) 2024-03-19
CO2023007768A2 (es) 2023-09-29
KR20230137889A (ko) 2023-10-05
JP2024505328A (ja) 2024-02-06
WO2022129925A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2023007032A (es) Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas.
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2021003435A (es) Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
MX2021007376A (es) Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados.
PH12019502283A1 (en) Anti-lag3 antibodies
BR112021022504A2 (pt) Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos
BR112021022576A2 (pt) Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201991997A1 (ru) Комбинированная терапия
CY1119599T1 (el) Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
MX2022002489A (es) Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
BR112018070139A2 (pt) expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos